Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,455 people get ASTM articles and Market Currents by email alert.

Get email alerts on ASTM »

ASTM

Aastrom Biosciences, Inc.

5/23/2013, 10:03 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 11:15 AM Aastrom Biosciences (ASTM -4.1%) slips today despite posting a Q1 net loss of -$0.15, which was narrower than the prior year and beat analysts estimates for a loss of $0.19 per share. The company also reported cash guidance, saying that it had a total of $9.2M in cash and cash equivalents, compared to $13.6 million in cash and cash equivalents in December. The cash used for operations during Q1 came to $6.8M. Comment! [Healthcare, On the Move, Earnings]
Wednesday, May 8, 6:50 PM Aastrom (ASTM): Q1 EPS of -$0.15 beats by $0.04. Revenue of $8K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 4, 3:43 PM Aastrom Biosciences (ASTM -1.9%) says the first patients have been enrolled in its ixCELL-DCM clinical trial, a study to assess the efficacy and safety of ixmyelocel-T in treating patients with advanced heart failure due to ischaemic dilated cardiomyopathy. The planned enrollment is for 108 patients at approximately 30 sites across the US. Comment! [Healthcare]
Thursday, March 28, 3:19 PM The carnage in Aastrom Biosciences (ASTM -0.2%) appears to have abated, at least for now, as the stock drifts sideways after being down about 1.4% in pre-market trading. The drug developer sank nearly 38% yesterday to a new 52-week low after saying it was cutting about half of its workforce and making a strategic change in R&D programs, including halting late-stage trials of ixmyelocel-T for treating critical limb ischemia, instead turning its focus to treating dilated cardiomyopathy. Comment! [Healthcare]
Wednesday, March 27, 12:54 PM Midday top 10 gainers: CHCI +45%. RVLT +35%. UEPS +24%. LIVE +20%. UTSI +20%. ECYT +11%. MFRM +10%. STSI +10%. PGTI +10%. GSL +10%.
Midday top 10 losers: ASTM -38%. EVBS -23%. ISNS -19%. ATOS -14%. CLF -15%. BAA -13%. GV -12%. LOGM -11%. MBLX -11%. LEDS -10%. Comment! [On the Move]
Wednesday, March 27, 9:32 AM Aastrom Biosciences (ASTM) craters 32% out the gate after saying it plans to cut its staff and operating costs by 50%, and end Phase III trials of its ixmyelocel-T drug for patients with critical limb ischemia - when there is an sudden lack of blood flow to a limb - as it was unable to bring in a partner. Instead, Aastrom will focus on Phase 2b trials of ixCELL for treating dilated cardiomyopathy (heart muscle disease). (PR) 2 Comments [Healthcare, On the Move]
Wednesday, March 27, 9:25 AM Premarket gainers: CHCI +51%. UTSI +23%. STSI +14%. VELT +12%. CHTP +11%.
Losers: ASTM -37%. CLF -14%. GV -7%. LNDC -6%. Comment! [On the Move]
Tuesday, March 19, 2:52 PM Aastrom Biosciences (ASTM -7.8%) trades near its 52-week low today, after the company reported bigger Q4 losses Y/Y in yesterday's after hours session. Bottom line margins were hit hard by heavy SG&A charges for non-cash stock based compenstation, plus higher overall R&D costs. 1 Comment [Healthcare, On the Move, Earnings]
Monday, March 18, 5:20 PM More on Aastrom Biosciences (ASTM): Q4 beats but losses more than double Y/Y, primarily due to charges and an increases in R&D expenses. Comment! [Healthcare, Earnings]
Monday, March 18, 4:13 PM Aastrom (ASTM): Q4 EPS of -$0.18 beats by $0.05. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, October 4, 2012, 4:14 PM Aastrom Biosciences (ASTM) says that president and CEO Tim Mayleben has decided to retire once the company has hired a successor. Mayleben will continue to serve as a member of the board of directors after the transition. The company notes that it's initiated a search for a new chief executive. Shares -0.6% AH. Comment! [Healthcare]
Wednesday, August 8, 2012, 9:10 AM Premarket gainers: WFR +31%. DF +28%. RAX +14%. LAMR +13%. CBB +12%. SODA +8%. CLWR +7%. KTOS +7%. ESRX +6%. HPQ +6%.
Losers: EZCH -21%. GIVN -16%. PCLN -15%. ATRS -9%. ASTM -9%. WCRX -8%. RL -7%. EXAS -5%. RENN -5%. Comment! [On the Move]
Friday, March 9, 2012, 11:38 AM Shares of Aastrom Biosciences (ASTM) come off a trading halt up 20.5% after the company says it landed a $40M private placement for its Series B convertible stock that helps it raise capital without diluting common stock shareholders for 5 years. Comment! [On the Move, Healthcare]
Monday, September 19, 2011, 1:06 PM Drug developer Aastrom (ASTM +5.2%) is trading higher after saying the 12-month follow-up data from clinical trials for its drug ixmyelocel-T showed that treatment was well-tolerated, and efficacy observations were consistent with improved heart function. Comment! [Healthcare, On the Move]
Friday, April 29, 2011, 11:53 AM A 2-1 ruling by a federal appeals court overturns a ban on federal stem-cell funding. STEM +8.1%, ASTM +2.6%, GERN +1%, CYTX +0.4%; PowerShares biotech and genome ETF (PBE) +0.3%. 6 Comments [Healthcare, On the Move]
Tuesday, January 18, 2011, 9:00 AM Premarket gainers: ARIA +33%. SBIB +19%. HEV +10%. CXDC +9%. VOD +5%. TGB +4%. ERJ +4%. ASTM +4%. SNN +4%.
Losers: CMA -6%. AAPL -5%. AVGO -5%. C -5%. WLOCD -4%. GSK -4%. Comment!